Arecor Therapeutics (LSE:AREC) EV-to-Revenue : 8.41 (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arecor Therapeutics's enterprise value is £38.46 Mil. Arecor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £4.57 Mil. Therefore, Arecor Therapeutics's EV-to-Revenue for today is 8.41.

The historical rank and industry rank for Arecor Therapeutics's EV-to-Revenue or its related term are showing as below:

LSE:AREC' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.2 Med: 32.12 Max: 67.94
Current: 8.41

During the past 7 years, the highest EV-to-Revenue of Arecor Therapeutics was 67.94. The lowest was 7.20. And the median was 32.12.

LSE:AREC's EV-to-Revenue is ranked worse than
50.72% of 1043 companies
in the Biotechnology industry
Industry Median: 8.21 vs LSE:AREC: 8.41

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Arecor Therapeutics's stock price is £1.465. Arecor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.15. Therefore, Arecor Therapeutics's PS Ratio for today is 9.77.

Arecor Therapeutics EV-to-Revenue Historical Data

The historical data trend for Arecor Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics EV-to-Revenue Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

80.53

25.37

10.82

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial					80.53	-	25.37	-	10.82

Competitive Comparison of Arecor Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Arecor Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's EV-to-Revenue falls into.

Arecor Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Arecor Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	38.455	/	4.573
	=	8.41

Arecor Therapeutics's current Enterprise Value is £38.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £4.57 Mil.

Arecor Therapeutics (LSE:AREC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Arecor Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.465	/	0.15
	=	9.77

Arecor Therapeutics's share price for today is £1.465.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.15.

Arecor Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.